162698-41-1Relevant articles and documents
3-(4,5-substituted pyrimidinamine) phenyl derivatives and application thereof
-
Paragraph 0107-0109, (2017/08/15)
The invention discloses 3-(4,5-substituted pyrimidinamine) phenyl derivatives and application thereof. The 3-(4,5-substituted pyrimidinamine) phenyl derivatives are compounds having a structure as shown in a formula (I) or pharmacologically acceptable sal
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
Bradbury, Robert H.,Callis, Rowena,Carr, Gregory R.,Chen, Huawei,Clark, Edwin,Feron, Lyman,Glossop, Steve,Graham, Mark A.,Hattersley, Maureen,Jones, Chris,Lamont, Scott G.,Ouvry, Gilles,Patel, Anil,Patel, Joe,Rabow, Alfred A.,Roberts, Craig A.,Stokes, Stephen,Stratton, Natalie,Walker, Graeme E.,Ward, Lara,Whalley, David,Whittaker, David,Wrigley, Gail,Waring, Michael J.
, p. 7801 - 7817 (2016/10/22)
Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical
HETEROCYCLIC COMPOUND
-
Page/Page column 59-60, (2010/07/08)
The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
Novel 5-HT2A receptor ligands
-
Page/Page column 6, (2010/02/11)
Compounds of formula I: are antagonists of the human 5-HT2A receptor, and hence useful in treatment or prevention of a variety of neurological conditions.